Cargando…

Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)

OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESE...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggenenti, Piero, Iliev, Ilian, Costa, Grazia Maria, Parvanova, Aneliya, Perna, Annalisa, Giuliano, Giovanni Antonio, Motterlini, Nicola, Ene-Iordache, Bogdan, Remuzzi, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494629/
https://www.ncbi.nlm.nih.gov/pubmed/18443191
http://dx.doi.org/10.2337/dc08-0371
_version_ 1782158234790920192
author Ruggenenti, Piero
Iliev, Ilian
Costa, Grazia Maria
Parvanova, Aneliya
Perna, Annalisa
Giuliano, Giovanni Antonio
Motterlini, Nicola
Ene-Iordache, Bogdan
Remuzzi, Giuseppe
author_facet Ruggenenti, Piero
Iliev, Ilian
Costa, Grazia Maria
Parvanova, Aneliya
Perna, Annalisa
Giuliano, Giovanni Antonio
Motterlini, Nicola
Ene-Iordache, Bogdan
Remuzzi, Giuseppe
author_sort Ruggenenti, Piero
collection PubMed
description OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS—Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18–0.65], P = 0.0012 unadjusted, and 0.35 [0.18–0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS—ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population.
format Text
id pubmed-2494629
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-24946292009-08-01 Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Ruggenenti, Piero Iliev, Ilian Costa, Grazia Maria Parvanova, Aneliya Perna, Annalisa Giuliano, Giovanni Antonio Motterlini, Nicola Ene-Iordache, Bogdan Remuzzi, Giuseppe Diabetes Care Cardiovascular and Metabolic Risk OBJECTIVE—In patients with type 2 diabetes, left ventricular hypertrophy (LVH) predicts cardiovascular events, and the prevention of LVH is cardioprotective. We sought to compare the effect of ACE versus non-ACE inhibitor therapy on incident electrocardiographic (ECG) evidence of LVH (ECG-LVH). RESEARCH DESIGN AND METHODS—This prespecified study compared the incidence of ECG-LVH by Sokolow-Lyon and Cornell voltage criteria in 816 hypertensive type 2 diabetic patients of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT), who had no ECG-LVH at baseline and were randomly assigned to at least 3 years of blinded ACE inhibition with trandolapril (2 mg/day) or to non-ACE inhibitor therapy. Treatment was titrated to systolic/diastolic blood pressure <130/80 mmHg. ECG readings were centralized and blinded to treatment. RESULTS—Baseline characteristics of the two groups were similar. Over a median (interquartile range) follow-up of 36 (24–48) months, 13 of the 423 patients (3.1%) receiving trandolapril compared with 31 of the 376 patients (8.2%) receiving non-ACE inhibitor therapy developed ECG-LVH (hazard ratio [HR] 0.34 [95% CI 0.18–0.65], P = 0.0012 unadjusted, and 0.35 [0.18–0.68], P = 0.0018 adjusted for predefined baseline covariates). The HR was significant even after adjustment for follow-up blood pressure and blood pressure reduction versus baseline. Compared with baseline, both Sokolow-Lyon and Cornell voltages significantly decreased with trandolapril but did not change with non-ACE inhibitor therapy. CONCLUSIONS—ACE inhibition has a specific protective effect against the development of ECG-LVH that is additional to its blood pressure–lowering effect. Because ECG-LVH is a strong cardiovascular risk factor in people with hypertension and diabetes, early ACE inhibition may be cardioprotective in this population. American Diabetes Association 2008-08 /pmc/articles/PMC2494629/ /pubmed/18443191 http://dx.doi.org/10.2337/dc08-0371 Text en Copyright © 2008, American Diabetes Association Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Cardiovascular and Metabolic Risk
Ruggenenti, Piero
Iliev, Ilian
Costa, Grazia Maria
Parvanova, Aneliya
Perna, Annalisa
Giuliano, Giovanni Antonio
Motterlini, Nicola
Ene-Iordache, Bogdan
Remuzzi, Giuseppe
Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title_full Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title_fullStr Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title_full_unstemmed Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title_short Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)
title_sort preventing left ventricular hypertrophy by ace inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the bergamo nephrologic diabetes complications trial (benedict)
topic Cardiovascular and Metabolic Risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494629/
https://www.ncbi.nlm.nih.gov/pubmed/18443191
http://dx.doi.org/10.2337/dc08-0371
work_keys_str_mv AT ruggenentipiero preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT ilievilian preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT costagraziamaria preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT parvanovaaneliya preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT pernaannalisa preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT giulianogiovanniantonio preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT motterlininicola preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT eneiordachebogdan preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT remuzzigiuseppe preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict
AT preventingleftventricularhypertrophybyaceinhibitioninhypertensivepatientswithtype2diabetesaprespecifiedanalysisofthebergamonephrologicdiabetescomplicationstrialbenedict